After Needham and H.C. Wainwright gave Akebia Therapeutics (NASDAQ: AKBA) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Mara Goldstein maintained a Buy rating on Akebia Therapeutics yesterday and set a price target of $6.00. The company’s shares closed last Tuesday at $2.15.
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 7.2% and a 36.5% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Neoleukin Therapeutics, and Autolus Therapeutics.
Currently, the analyst consensus on Akebia Therapeutics is a Strong Buy with an average price target of $7.67, a 237.9% upside from current levels. In a report issued on February 22, Piper Sandler also maintained a Buy rating on the stock with a $8.00 price target.
Akebia Therapeutics’ market cap is currently $377.9M and has a P/E ratio of -1.13.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AKBA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Read More on AKBA:
- Stifel Nicolaus Maintains a Hold Rating on ContextLogic (WISH)
- Organogenesis Holdings (ORGO) Receives a Buy from BTIG
- Mizuho Securities Reaffirms Their Buy Rating on CytomX Therapeutics (CTMX)
- Mizuho Securities Thinks Neoleukin Therapeutics’ Stock is Going to Recover
- BRP Group (BRP) Receives a Buy from Wells Fargo